Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Notes Payables (2024 - 2025)

Nuvation Bio (NUVB) has disclosed Notes Payables for 2 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Notes Payables fell 8.9% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.7 million, a 8.9% decrease, with the full-year FY2025 number at $5.7 million, down 8.9% from a year prior.
  • Notes Payables was $5.7 million for Q4 2025 at Nuvation Bio, up from $5.6 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $11.6 million in Q2 2024 to a low of $5.6 million in Q2 2025.